Silverback Therapeutics (Silverback Therapeutics) Quick Ratio : 67.87 (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Silverback Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Silverback Therapeutics's quick ratio for the quarter that ended in Sep. 2022 was 67.87.

Silverback Therapeutics has a quick ratio of 67.87. It generally indicates good short-term financial strength.

The historical rank and industry rank for Silverback Therapeutics's Quick Ratio or its related term are showing as below:

SBTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.59 Med: 19.9 Max: 67.87
Current: 67.87

During the past 4 years, Silverback Therapeutics's highest Quick Ratio was 67.87. The lowest was 0.59. And the median was 19.90.

SBTX's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.485 vs SBTX: 67.87

Silverback Therapeutics Quick Ratio Historical Data

The historical data trend for Silverback Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silverback Therapeutics Quick Ratio Chart

Silverback Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Quick Ratio

4.04

0.59

40.69

17.56

Silverback Therapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Quick Ratio	Get a 7-Day Free Trial									19.90	17.56	17.65	23.61	67.87

Competitive Comparison of Silverback Therapeutics's Quick Ratio

For the Biotechnology subindustry, Silverback Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silverback Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silverback Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Silverback Therapeutics's Quick Ratio falls into.

Silverback Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Silverback Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Quick Ratio (A: Dec. 2021 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(261.492	-	0)	/	14.892
	=	17.56

Silverback Therapeutics's Quick Ratio for the quarter that ended in Sep. 2022 is calculated as

Quick Ratio (Q: Sep. 2022 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(270.799	-	0)	/	3.99
	=	67.87

Silverback Therapeutics (NAS:SBTX) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

Silverback Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Silverback Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Silverback Therapeutics (Silverback Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silverback Therapeutics Inc (NAS:SBTX) » Definitions » Quick Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Fairview Avenue N, Suite 600, Seattle, WA, USA, 98109

Website

https://www.silverbacktx.com

Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

Executives

Brian Dorsey	officer: Chief Operating Officer	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Alexander A Fitzpatrick	officer: Chief Legal Officer	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Pratik Shah Living Trust Dated June 15, 2011	10 percent owner	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Michael Kelly	director	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Rajeev Dadoo	director	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Sarina Tanimoto	10 percent owner, officer: Chief Medical Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Eric Karas	officer: Chief Commercial Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Justin Chakma	officer: Chief Business Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Richard E Lowenthal	director, 10 percent owner, officer: President and CEO	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Pratik Shah	director, 10 percent owner	3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kathleen D. Scott	officer: Chief Financial Officer	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Deerfield Mgmt Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017